Phase 4Not yet recruiting
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Unresectable or Metastatic Melanoma in India.
- Sponsor
- Bristol-Myers Squibb (Industry)
- Enrollment
- 40 planned
- Conditions
- Unresectable Melanoma; Metastatic Melanoma
- Interventions
- Nivolumab + Relatlimab
- Ages
- children, adults, older adults
- Registry
- NCT07459543
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.
Primary outcomes
- Incidence of adverse events (AEs)
- Incidence of drug-related AEs
- Incidence of serious adverse events (SAEs)
- Incidence of drug-related SAEs
History
Study completion expected
Primary completion expected
Expected to start
Last registry update
Registered